Literature DB >> 33641009

Heterogeneity in α-synuclein fibril activity correlates to disease phenotypes in Lewy body dementia.

Arpine Sokratian1, Julia Ziaee1, Kaela Kelly1, Allison Chang1, Nicole Bryant1, Shijie Wang1, Enquan Xu1, Joshua Y Li1, Shih-Hsiu Wang2,3, John Ervin2,3, Sandip M Swain4, Rodger A Liddle4, Andrew B West5,6.   

Abstract

α-Synuclein aggregation underlies pathological changes in Lewy body dementia. Recent studies highlight structural variabilities associated with α-synuclein aggregates in patient populations. Here, we develop a quantitative real-time quaking-induced conversion (qRT-QuIC) assay to measure permissive α-synuclein fibril-templating activity in tissues and cerebrospinal fluid (CSF). The assay is anchored through reference panels of stabilized ultra-short fibril particles. In humanized α-synuclein transgenic mice, qRT-QuIC identifies differential levels of fibril activity across the brain months before the deposition of phosphorylated α-synuclein in susceptible neurons. α-Synuclein fibril activity in cortical brain extracts from dementia with Lewy bodies (DLB) correlates with activity in matched ventricular CSF. Elevated α-synuclein fibril activity in CSF corresponds to reduced survival in DLB. α-Synuclein fibril particles amplified from cases with high fibril activity show superior templating in the formation of new inclusions in neurons relative to the same number of fibril particles amplified from DLB cases with low fibril activity. Our results highlight a previously unknown broad heterogeneity of fibril-templating activities in DLB that may contribute to disease phenotypes. We predict that quantitative assessments of fibril activities in CSF that correlate to fibril activities in brain tissue will help stratify patient populations as well as measure therapeutic responses to facilitate the development of α-synuclein-targeted therapeutics.

Entities:  

Keywords:  Aggregation; Biomarker; Neurodegeneration; Parkinson’s disease; Prion; SNCA

Year:  2021        PMID: 33641009      PMCID: PMC8055043          DOI: 10.1007/s00401-021-02288-1

Source DB:  PubMed          Journal:  Acta Neuropathol        ISSN: 0001-6322            Impact factor:   17.088


  52 in total

1.  Characterization of the nanoscale properties of individual amyloid fibrils.

Authors:  Jeffrey F Smith; Tuomas P J Knowles; Christopher M Dobson; Cait E Macphee; Mark E Welland
Journal:  Proc Natl Acad Sci U S A       Date:  2006-10-12       Impact factor: 11.205

Review 2.  Amyloid beta: structure, biology and structure-based therapeutic development.

Authors:  Guo-Fang Chen; Ting-Hai Xu; Yan Yan; Yu-Ren Zhou; Yi Jiang; Karsten Melcher; H Eric Xu
Journal:  Acta Pharmacol Sin       Date:  2017-07-17       Impact factor: 6.150

3.  Seeding variability of different alpha synuclein strains in synucleinopathies.

Authors:  Niccolò Candelise; Matthias Schmitz; Franc Llorens; Anna Villar-Piqué; Maria Cramm; Tobias Thom; Susana Margarida da Silva Correia; José Eriton Gomes da Cunha; Wiebke Möbius; Tiago F Outeiro; Valentina González Álvarez; Martina Banchelli; Cristiano D'Andrea; Marella de Angelis; Saima Zafar; Alberto Rabano; Paolo Matteini; Inga Zerr
Journal:  Ann Neurol       Date:  2019-03-27       Impact factor: 10.422

4.  Fragmentation of fiberlike structures: sonication studies of cylindrical block copolymer micelles and behavioral comparisons to biological fibrils.

Authors:  Gérald Guérin; Hai Wang; Ian Manners; Mitchell A Winnik
Journal:  J Am Chem Soc       Date:  2008-10-11       Impact factor: 15.419

5.  Low sensitivity in clinical diagnoses of dementia with Lewy bodies.

Authors:  Peter T Nelson; Gregory A Jicha; Richard J Kryscio; Erin L Abner; Frederick A Schmitt; Gregory Cooper; Li O Xu; Charles D Smith; William R Markesbery
Journal:  J Neurol       Date:  2009-10-01       Impact factor: 4.849

Review 6.  Diagnosis and management of dementia with Lewy bodies: Fourth consensus report of the DLB Consortium.

Authors:  Ian G McKeith; Bradley F Boeve; Dennis W Dickson; Glenda Halliday; John-Paul Taylor; Daniel Weintraub; Dag Aarsland; James Galvin; Johannes Attems; Clive G Ballard; Ashley Bayston; Thomas G Beach; Frédéric Blanc; Nicolaas Bohnen; Laura Bonanni; Jose Bras; Patrik Brundin; David Burn; Alice Chen-Plotkin; John E Duda; Omar El-Agnaf; Howard Feldman; Tanis J Ferman; Dominic Ffytche; Hiroshige Fujishiro; Douglas Galasko; Jennifer G Goldman; Stephen N Gomperts; Neill R Graff-Radford; Lawrence S Honig; Alex Iranzo; Kejal Kantarci; Daniel Kaufer; Walter Kukull; Virginia M Y Lee; James B Leverenz; Simon Lewis; Carol Lippa; Angela Lunde; Mario Masellis; Eliezer Masliah; Pamela McLean; Brit Mollenhauer; Thomas J Montine; Emilio Moreno; Etsuro Mori; Melissa Murray; John T O'Brien; Sotoshi Orimo; Ronald B Postuma; Shankar Ramaswamy; Owen A Ross; David P Salmon; Andrew Singleton; Angela Taylor; Alan Thomas; Pietro Tiraboschi; Jon B Toledo; John Q Trojanowski; Debby Tsuang; Zuzana Walker; Masahito Yamada; Kenji Kosaka
Journal:  Neurology       Date:  2017-06-07       Impact factor: 9.910

Review 7.  Diagnosis and management of dementia with Lewy bodies: third report of the DLB Consortium.

Authors:  I G McKeith; D W Dickson; J Lowe; M Emre; J T O'Brien; H Feldman; J Cummings; J E Duda; C Lippa; E K Perry; D Aarsland; H Arai; C G Ballard; B Boeve; D J Burn; D Costa; T Del Ser; B Dubois; D Galasko; S Gauthier; C G Goetz; E Gomez-Tortosa; G Halliday; L A Hansen; J Hardy; T Iwatsubo; R N Kalaria; D Kaufer; R A Kenny; A Korczyn; K Kosaka; V M Y Lee; A Lees; I Litvan; E Londos; O L Lopez; S Minoshima; Y Mizuno; J A Molina; E B Mukaetova-Ladinska; F Pasquier; R H Perry; J B Schulz; J Q Trojanowski; M Yamada
Journal:  Neurology       Date:  2005-10-19       Impact factor: 9.910

8.  Potent prion-like behaviors of pathogenic α-synuclein and evaluation of inactivation methods.

Authors:  Airi Tarutani; Tetsuaki Arai; Shigeo Murayama; Shin-Ichi Hisanaga; Masato Hasegawa
Journal:  Acta Neuropathol Commun       Date:  2018-04-18       Impact factor: 7.801

9.  Best Practices for Generating and Using Alpha-Synuclein Pre-Formed Fibrils to Model Parkinson's Disease in Rodents.

Authors:  Nicole K Polinski; Laura A Volpicelli-Daley; Caryl E Sortwell; Kelvin C Luk; Nunilo Cremades; Lindsey M Gottler; Jessica Froula; Megan F Duffy; Virginia M Y Lee; Terina N Martinez; Kuldip D Dave
Journal:  J Parkinsons Dis       Date:  2018       Impact factor: 5.568

10.  α-Synuclein strains target distinct brain regions and cell types.

Authors:  Angus Lau; Raphaella W L So; Heather H C Lau; Jason C Sang; Alejandro Ruiz-Riquelme; Shelaine C Fleck; Erica Stuart; Sindhu Menon; Naomi P Visanji; Georg Meisl; Rania Faidi; Maria M Marano; Cian Schmitt-Ulms; Zhilan Wang; Paul E Fraser; Anurag Tandon; Bradley T Hyman; Holger Wille; Martin Ingelsson; David Klenerman; Joel C Watts
Journal:  Nat Neurosci       Date:  2019-12-02       Impact factor: 24.884

View more
  10 in total

Review 1.  Seed amplification and RT-QuIC assays to investigate protein seed structures and strains.

Authors:  Heidi G Standke; Allison Kraus
Journal:  Cell Tissue Res       Date:  2022-03-08       Impact factor: 5.249

2.  α-Synuclein molecular behavior and nigral proteomic profiling distinguish subtypes of Lewy body disorders.

Authors:  Ivan Martinez-Valbuena; Emily Swinkin; Enrique Santamaria; Joaquin Fernandez-Irigoyen; Valerie Sackmann; Ain Kim; Jun Li; Paulina Gonzalez-Latapi; Greg Kuhlman; Suvorit Subhas Bhowmick; Naomi P Visanji; Anthony E Lang; Gabor G Kovacs
Journal:  Acta Neuropathol       Date:  2022-06-24       Impact factor: 15.887

3.  Pathological α-synuclein recruits LRRK2 expressing pro-inflammatory monocytes to the brain.

Authors:  Enquan Xu; Ravindra Boddu; Hisham A Abdelmotilib; Arpine Sokratian; Kaela Kelly; Zhiyong Liu; Nicole Bryant; Sidhanth Chandra; Samantha M Carlisle; Elliot J Lefkowitz; Ashley S Harms; Etty N Benveniste; Talene A Yacoubian; Laura A Volpicelli-Daley; David G Standaert; Andrew B West
Journal:  Mol Neurodegener       Date:  2022-01-10       Impact factor: 14.195

4.  Similar neuronal imprint and no cross-seeded fibrils in α-synuclein aggregates from MSA and Parkinson's disease.

Authors:  Francesca De Giorgi; François Ichas; Florent Laferrière; Stéphane Claverol; Erwan Bezard
Journal:  NPJ Parkinsons Dis       Date:  2022-01-13

5.  High diagnostic performance of independent alpha-synuclein seed amplification assays for detection of early Parkinson's disease.

Authors:  Marco J Russo; Christina D Orru; Luis Concha-Marambio; Simone Giaisi; Bradley R Groveman; Carly M Farris; Bret Holguin; Andrew G Hughson; David-Erick LaFontant; Chelsea Caspell-Garcia; Christopher S Coffey; Jennifer Mollon; Samantha J Hutten; Kalpana Merchant; Roland G Heym; Claudio Soto; Byron Caughey; Un Jung Kang
Journal:  Acta Neuropathol Commun       Date:  2021-11-06       Impact factor: 7.801

6.  Evaluation of ABT-888 in the amelioration of α-synuclein fibril-induced neurodegeneration.

Authors:  Lyndsay Hastings; Arpine Sokratian; Daniel J Apicco; Christina M Stanhope; Lindsey Smith; Warren D Hirst; Andrew B West; Kaela Kelly
Journal:  Brain Commun       Date:  2022-02-22

Review 7.  RT-QuIC and Related Assays for Detecting and Quantifying Prion-like Pathological Seeds of α-Synuclein.

Authors:  Ankit Srivastava; Parvez Alam; Byron Caughey
Journal:  Biomolecules       Date:  2022-04-14

Review 8.  Proteolytic α-Synuclein Cleavage in Health and Disease.

Authors:  Alexandra Bluhm; Sarah Schrempel; Stephan von Hörsten; Anja Schulze; Steffen Roßner
Journal:  Int J Mol Sci       Date:  2021-05-21       Impact factor: 5.923

Review 9.  The Effects of Statins on Neurotransmission and Their Neuroprotective Role in Neurological and Psychiatric Disorders.

Authors:  Michał Kosowski; Joanna Smolarczyk-Kosowska; Marcin Hachuła; Mateusz Maligłówka; Marcin Basiak; Grzegorz Machnik; Robert Pudlo; Bogusław Okopień
Journal:  Molecules       Date:  2021-05-11       Impact factor: 4.411

Review 10.  α-Synuclein Strains: Does Amyloid Conformation Explain the Heterogeneity of Synucleinopathies?

Authors:  Simon Oliver Hoppe; Gamze Uzunoğlu; Carmen Nussbaum-Krammer
Journal:  Biomolecules       Date:  2021-06-23
  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.